Status:
COMPLETED
Augmenting Exposure Therapy With an N-Methyl-D-Aspartate (NMDA) Agonist for Panic Disorder
Lead Sponsor:
Hartford Hospital
Conditions:
Panic Disorder
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study involves cognitive behavioral therapy (CBT) and a medication called D-cycloserine (DCS), which is thought to help reduce panic symptoms more effectively by interacting with N-methyl-D-aspar...
Detailed Description
This study consists of cognitive behavioral therapy (CBT) including exposure to physical sensations and feared situations, which have been demonstrated to be effective for many individuals with panic ...
Eligibility Criteria
Inclusion
- Principal diagnosis of panic disorder
Exclusion
- History of psychotic disorders or bipolar disorder
- Substance dependence
- Pregnant or breastfeeding
- History of a medical condition that may increase the risks of taking the study drug
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
End Date :
March 1 2007
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00131339
Start Date
November 1 2004
End Date
March 1 2007
Last Update
August 26 2009
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hartford Hospital
Hartford, Connecticut, United States, 06106
2
Center for Anxiety and Related Disorders at Boston University
Boston, Massachusetts, United States, 02215